Bellevue Group
 | |
| Company type | Public |
|---|---|
| ISIN | CH0028422100 [2] |
| Industry | Investment management |
| Founded | 1993 [3] |
| Founders |
|
| Headquarters | Küsnacht, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | |
| AUM |  CHF 9.4 billion (2022) [4] |
| Website | bellevue |
Bellevue Group AG, headquartered in Küsnacht, is a listed investment management corporation from Switzerland.[3] Bellevue Group consists of the subsidiaries Bellevue Asset Management, Bellevue Private Markets and StarCapital. It has 9,6 billion Swiss francs Assets Under Management[4][5] Around 80% of clients assets are in healthcare investments.[5] Bellevue Group is also active in alternative investments and private equity, including co-investments in private domestic small and medium-sized enterprises. In this business area, client assets under management were 1.0 billion francs as of mid-2021.[6]
Bellevue Group is among the largest investors in the health care segment worldwide. It has subsidiaries in Germany, UK and USA, and is focusing on platform companies with products in phase two trials or later who preferably develop technologies that can be applied in multiple ways.[7] One of the Bellevue Asset Management teams manages the BB Biotech investment company. The former investment company BB Medtech, which was converted into an equity fund at the end of September 2009, is also managed by Bellevue Asset Management. Bellevue Entrepreneur Private launched in 2021 is part of the private equity business dealing with financing the growth of small and medium-sized Swiss enterprises with a fund that co-invests with entrepreneurial families.[6]
History[edit]
The group was founded in 1993 by Marting Bisang, Jürg Schäppi, Hans-Jörg Graf, Daniel Schlatter and Dieter Albrecht. Martin Bisang is still the largest shareholder. The group early on became an important provider in brokerage and block deals on the Swiss market.[8]
In 2014, Bellevue Group acquired investment funds from Zurich Cantonal Bank: Adamant Biomedical Investments.[9]
The venture capital fund BB Pureos Bioventures founded in 2017 specialises in emerging modalities such as nucleic acid, cell- and gene therapies.[10]
With the acquisition of StarCapital for 30 to 40 million francs in 2016 Bellevue Group wanted to increase its service range and presence in Germany.[11][12][5] In 2022 Star Capital was integrated into Bellevue Group with Bellevue's German business entirely managed from Frankfurt from this point on.[13] After former owner Peter Huber had left the company, Assets under Management have been considerably reduced.[5]
As part of restructuring and refocusing, Bellevue Group discontinued its brokerage and corporate finance activities in 2017.[14] The attempts of creating a wealth management department were revised until 2020.[5] In 2020, Bellevue sold its banking operations with underlying assets of CHF 1.6 billion to Quintet private bank and became a pure asset manager.[15][16] Before that Bellevue had sold its stake in the Swiss stock market SIX to Credit Suisse.[17]
In autumn 2020, investor and billionaire Hansjörg Wyss took a 9.7 percent stake in Bellevue Group. This means that the anchor shareholders (31.6 percent: Martin Bisang, Manuela and Jürg Schäppi) together with the employees (11.4 percent) and Wyss hold the majority of shares in Bellevue Group.[18][5]
In 2022, Bellevue Group started to expand into Asia through its Singapore office on a systematical basis.[19] Since 2023, Bellevue Group Private Markets started to get active in the Private Equity secondary market.[20]
References[edit]
- ^ "Bellevue Group N". SIX Swiss Exchange. Retrieved 28 September 2023.
- ^ "ISIN: CH0028422100". Retrieved 28 September 2023.
- ^ a b "Bellevue Group". Bloomberg. Retrieved 28 September 2023.
- ^ a b "Bellevue's Profits and Managed Assets Suffer in First Half". Finews. 27 July 2023. Retrieved 28 September 2023.
- ^ a b c d e f Hody, Peter (2 March 2021). "Bellevue Group: Shareholder-Friendly Writedowns". Finews. Retrieved 28 September 2023.
- ^ a b "Bellevue Group Quadruples First-Half Profit". Finews. 29 July 2021. Retrieved 28 September 2023.
- ^ McDougall, Mary (11 April 2022). "Bellevue's Paul Major: investing to solve healthcare problems". Investors' Chronicle. Retrieved 28 September 2023.
- ^ "Bellevue Group: Ein Abstieg in Raten" (in German). Handelszeitung. 2 September 2019. Retrieved 28 September 2023.
- ^ "Bellevue Group AG concludes acquisition of Adamant Biomedical Investments AG". Reuters. 1 October 2014. Retrieved 28 September 2023.
- ^ "Bellevue Asset Management: Pureos Bioventures expands fund size to USD 205 million". Moneycab. 22 April 2021. Retrieved 28 September 2023.
- ^ "Bellevue Group completes acquisition of StarCapital". Reuters. 6 July 2016. Retrieved 28 September 2023.
- ^ "Bellevue Group to Broaden Business as Brokerage Income Erodes". Finews. 29 July 2016. Retrieved 28 September 2023.
- ^ "Former UBS Investment Strategist Joins Bellevue". Finews. 23 June 2022. Retrieved 28 September 2023.
- ^ "Bellevue Group could sell loss-making bank as revamp stalls". Reuters. 25 June 2019. Retrieved 28 September 2023.
- ^ "Bellevue a Soon-to-Be Pure Asset Manager". Finews. 28 January 2020. Retrieved 28 September 2023.
- ^ "Bellevue Sells Bank to KBL". Finews. 20 August 2019. Retrieved 28 September 2023.
- ^ Wicki, Florian (28 August 2019). "Swiss Bank Quietly Lifts SIX Stake". Finews. Retrieved 28 September 2023.
- ^ "BBillionaire Buys Stake in Swiss Finance Boutique". Finews. 21 October 2020. Retrieved 28 September 2023.
- ^ Baumann, Claude (2022-11-07). "Florin Boetschi: "Singapore is our first regional presence in Asia"". Finews.
- ^ Burroughes, Tom (2023-03-21). "In Tough Times, Private Market Secondaries Can Shine". Wealth Briefing.